Pyott explained that Allergan has responded to the Food and Drug Administration regarding the newcomer, pointing out several significant challenges and shortcomings that need to be addressed before a generic can come to market. Shortcuts are dangerous in the eye business, he said, and the FDA is aware of that.
Another worry for investors was a delay in Allergan's macular degeneration drug. Pyott said the product was indeed delayed but is not dead. Allergan is already recruiting patients for its new trial of the drug, which could be a gigantic opportunity for the company in 2017 and beyond.
Another bright spot for Allergan is, of course, Botox, which Pyott noted is ahead of plan in its many indications. In fact, he said, Botox gained share in the quarter globally, despite fierce competition. Botox now accounts for 80% of the world market.
Cramer said that Pyott had great answers for the concerns that were raised and he sees the stock as an opportunity at its current levels.
Money in MobileWe all know that mobile, social and the cloud are the next drivers of Internet success, but until now only Facebook (FB) has shown that it can make money in mobile. That was, of course, until Yelp shocked investors with sales rising by 69%. Cramer said that Yelp is winning in a number of different ways. First, as more and more people use the service, it becomes harder and harder for businesses of all types not to be on the service. And as more and more businesses get listed, well, that only drives more people to the site in a virtuous circle. Second, as Yelp grows its user base, it's also growing its advertisers because advertising to those people who are already interested in your business and are looking it up makes a lot of sense. Yelp is rapidly becoming the next generation yellow pages, said Cramer, and that's a very powerful concept. Finally, Cramer said that with Yelp's remarkable growth and dominant position, it becomes a natural takeover target, especially for a company like Apple (AAPL), a stock Cramer owns for his charitable trust,
Lightning RoundIn the Lightning Round, Cramer was bullish on Cheniere Energy Partners (CQP), DexCom (DXCM), Himax Technologies (HIMX), Pier 1 Imports (PIR), Celldex Therapeutics (CLDX) and Applied Materials (AMAT). Cramer was bearish on SunPower (SPWR) and Chart Industries (GTLS).
Executive Decision: Phil FernandezIn his second "Executive Decision" segment, Cramer sat down with Phil Fernandez, president and CEO of Marketo (MKTO - Get Report), the cloud marketing stock that's up nearly 45% since Cramer recommended it on June 10. Marketo just reported a stellar 62% rise in revenue for the quarter. Fernandez said Marketo is pioneering a new category of marketing and this quarter proved to investors the category is for real. He said Marketo allows its customers to communicate with their customers through multiple channels, a concept which is resonating with many companies. When asked about the company's many partnerships, Fernandez explained that what Marketo does is slightly different than what other vendors provide, which is why it is able to partner with companies including Microsoft (MSFT) and Salesforce.com (CRM), which, on the surface, appear to have competing products. With social media finally finding some advertising success, Fernandez said more and more advertisers are beginning to look at the platform, which only creates more success and makes Marketo more valuable since it can reach customers across those channels. Email, he said, is only a small part of engaging with customers in today's mobile and social world. When asked about the company's finances, Fernandez reassured shareholders that Marketo is not currently planning any major equity offerings. Cramer said he continues to like the Marketo story.
Executive Decision: Ron CohenIn a third "Executive Decision" segment, Cramer sat down with Dr. Ron Cohen, president and CEO of Acorda Therapeutics (ACOR - Get Report), a speculative biotech that's shot up 57% since Cramer recommended it back in June. Cohen said Acorda's drug, Ampyra, has currently been tried by 80,000 patients with MS, but there are still another 120,000 patients that have yet to try the drug. When asked how Acorda gets the drug into the hands of more patients, Cohen said that it's simply a matter of educating more doctors on its incredible results, which have shown improvement in walking for many patients. Acorda is not stopping with Ampyra, however, as Cohen noted that patients who have suffered a stroke can also benefit from Ampyra. The company is working on a new formulation for another clinical trial in the second quarter of 2014. Cohen said that one of the key benefits of Ampyra is that it interacts well with other drugs, so it can often be taken in conjunction with other medications. Cramer said Acorda remains an interesting speculative stock that investors should investigate. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts